Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05495568 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT05495568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05495568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Celltrion
Phase
Phase 3
Overall status
Completed
Start date
November 7, 2022
Completion date
February 5, 2024
Enrollment
367 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic plaque psoriasis